Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Disorders of Sex Development × STA 9090 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Fallopian Tube Neoplasms 2 Carcinoma, Ovarian Epithelial 2 Small Cell Lung Carcinoma 1 Sarcoma 1 Neurofibrosarcoma 1 Neoplasms 1 Lung Cancer - Malignant Pleural Mesothelioma 1 Disorders of Sex Development 1

Interventions

selinexor 1 pazopanib 1 STA 9090 1 Proton Therapy 1 Paclitaxel 1 Ifosfamide 1 Doxorubicin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02012192 2019-08-13

GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

Medical University Innsbruck

Phase 1/2 Terminated

133 enrolled 10 charts

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Disorders of Sex Development

Data powered by HemOnc (CC BY 4.0) Colophon ⚡